Methylene‐bearing sulfur‐containing cyanopyrimidine derivatives for treatment of cancer: Part‐II

Abstract

In continuation of our previous work on anticancer and anti‐inflammatory agents, a series of 22 novel methylene‐bearing sulfur‐containing cyanopyrimidine derivatives was synthesized by Biginelli condensation reaction, which was followed by nucleophilic substitution of the chloro group with secondary or tertiary amines. Structural confirmation of these derivatives was attained through different spectral techniques. Then, anticancer evaluation of these compounds was done at the National Cancer Institute. Compounds 4g, 4j, 4k, and 4v demonstrated appreciable results against different cell lines. Among the synthesized compounds, 4g (NSC: 795475) exhibited a growth inhibition (GI) of 81.34% against the NCI‐H460 lung cancer cell line, 72.64% against the ACHN renal cancer cell line, and 112.17% against the OVCAR‐4 ovarian cancer cell line. Compound 4j (NSC: 795746) was active against U‐251 CNS cancer, OVCAR‐4 ovarian cancer, and 786‐0 and ACHN renal cancer cell lines, with GI of 78.84%, 150.38%, 75.64%, and 86.45%, respectively. The literature supporting the association between cancer and underlying inflammation prompted us to evaluate the four compounds, 4g, 4j, 4k, and 4v, with appreciable anticancer activity for their in vitro anti‐inflammatory activity. Cyclooxygenase (COX)‐2 inhibition studies were also performed to study the molecular target. To validate the target study, molecular docking studies in the ligand‐binding domain of COX‐2 (PDB ID: 1CX2) were also performed. Compounds 4g, 4j, and 4k did not show cytotoxicity on RAW 264.7 cells up to 10 μM concentration; however, compound 4v showed cytotoxic effects at 10 μM concentration.